Join Anne Chiang, MD, PhD, Yale School of Medicine, a leading expert on small cell lung cancer, for an in-depth presentation on patient outcomes in extensive-small cell lung cancer. Dr. Chiang will present evidence-based advice regarding emerging therapies, strategies for targeted treatments and immunotherapy, optimization of individual patient treatment plans, managing adverse events, and much more! Don't miss this event! Register now!

Learn new advances in the treatment of relapsed or refractory immune thrombocytopenia, including treatment differentiation, efficacy and safety strategies, and much more. This activity features perspectives from two noted experts in the field, Dr. Keith McCrae, Director of Benign Hematology at the Cleveland Clinic Taussig Cancer Center; and Ms. Phyllis McKiernan, Advanced Practice Nurse in Blood & Marrow Stem Cell Transplantation at the John Theurer Cancer Center, Hackensack Meridian Health.

In the first segment of this three-part series, Maria Badillo, MSN, RN, OCN®, CCRP, Research Nurse Manager, MD Anderson Cancer Center, evaluates guideline recommendations for the management of patients with advanced diffuse large B-cell lymphoma (DLBCL). Learners will receive expert insight on assessing emerging data on novel therapies, strategies to manage adverse events, and optimizing treatment for patients with advanced DLBCL. Complete modules 2 and 3 for more in-depth knowledge of aggressive non-Hodgkin lymphoma. Start now!

In the second segment of this three-part series, Maria Badillo, MSN, RN, OCN®, CCRP, Research Nurse Manager, MD Anderson Cancer Center, shares expert insights on guideline recommendations for optimizing individual patient care, efficacy and safety data, and strategies to manage adverse event for patients with advanced aggressive mantle cell lymphoma (MCL). For more expert insights on aggressive non-Hodgkin lymphoma, complete modules 1 and 3. Start the activity now!

In the third segment of this three-part series, Maria Badillo, MSN, RN, OCN®, CCRP, Research Nurse Manager, MD, Anderson Cancer Center, evaulates guideline recommendations for the management of peripheral T-cell lymphoma (PTCL), assesses emerging data on novel therapies, and applies strategies to optimize treatment experiences for patients. For more expert insights on aggressive non-hodgkin lymphoma, complete modules 2 and 3. Start the activity now!

Discover new developments in the diagnosis and treatment of EGFR exon-20 Insertion–Mutant NSCLC and assess emerging efficacy and safety data on novel targeted therapies. This activity features expert insights from Helena Yu, MD, Memorial Sloan Kettering Cancer Center, and Maria Arcila, MD, Memorial Sloan Kettering Cancer Center. Start now!

In this CME/NCPD activity, D. Ross Camidge, MD, PhD, of the University of Colorado, and Beth Sandy, MSN, CRNP, OCN®, of the University of Pennsylvania, discuss novel treatments for advanced KRAS mutation-positive NSCLC and how to manage adverse events associated with small molecule inhibitors. Start now! 

In this NCPD activity, Mikel Ross, MSN, RN, AGPCNP-BC, OCN^®, CBCN, identifies prognostic markers that impact treatment selection and treatment goals to individual patients with metastatic breast cancer (MBC), evaluates the efficacy and safety profiles of novel therapies for HER2-positive, HER2-negative, and triple-negative MBC, and more. Complete the activity now to earn free NCPD!

This free online CME/NCPD activity on first-line and second-line treatment for advanced renal cell carcinoma is presented by Bradley McGregor, MD, and Robert Motzer, MD. It is also available as a podcast. Start the activity now!

This NCPD activity, presented by Laura S. Wood, RN, MSN, OCN^®, discusses mechanisms of action of IO agents and VEGFR TKIs, efficacy and safety profiles of IO and VEGFR TKI therapies, and strategies to improve treatment tolerability for advanced renal cell carcinoma. Start now! 

In this virtual tumor board, Vicki L. Keedy, MD, MSCI, Brian P. Rubin, MD, PhD, and Kathleen Polson, NP, discuss diagnostic evaluation, treatment selection, and supportive care strategies for patients with soft tissue sarcoma.

This NCPD activity, presented by Allison Miller Imahiyerobo, APN, includes cases that provide insight into nursing management of ITP. In addition, Ms. Miller Imahiyerobo discusses the pathogenesis of ITP and differentiates the efficacy and safety profiles of current and emerging ITP therapies. 

In this NCPD activity, Amy L. Goodrich, RN, MSN, CRNP-AC, evaluates guideline recommendations for the management of patients with advanced NHL, assesses emerging efficacy and safety data on novel therapies for advanced NHL, and applies strategies to manage adverse events and optimize treatment experiences for patients receiving novel therapies for NHL. Start now!